Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1622 1629
This examiner grants 35% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17437643 | COMPOSITIONS, METHODS FOR REGULATING UTERINE, PLACENTAL GROWTH | Non-Final OA | The Regents of the University of California |
| 17899272 | METHODS AND MATERIALS FOR ASSESSING AND TREATING ARTHRITIS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17256640 | COMPOSITIONS AND METHODS FOR MEDIATING EPS | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 19281019 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Final Rejection | Amgen Inc. |
| 19276294 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Non-Final OA | Hyloris Developments SA |
| 19237417 | IMPROVED MIRDAMETINIB TREATMENT | Non-Final OA | SpringWorks Therapeutics, Inc. |
| 19081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Non-Final OA | AVILAR THERAPEUTICS, INC. |
| 17597339 | COMPOSITIONS AND METHODS USING TRIGONELLINE TO PRODUCE INTRACELLULAR NAD+ | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17309435 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Final Rejection | Board of Regents of the University of Nebraska |
| 18638133 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | Final Rejection | University of South Florida |
| 17881038 | COMPOUNDS AND METHODS FOR FORMING ION CHANNELS IN BIOLOGICAL MEMBRANES | Final Rejection | Wisconsin Alumni Research Foundation |
| 17681560 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 17387129 | INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN | Final Rejection | Southwest Research Institute |
| 16617720 | TREATMENT OF DISEASES ASSOCIATED WITH A DYSREGULATION OF THE mTOR PATHWAY | Final Rejection | BIOCODEX |
| 17860498 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS | Non-Final OA | JAZZ PHARMACEUTICALS IRELAND LIMITED |
| 17518846 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | Final Rejection | Mind Medicine, Inc. |
| 17993868 | COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF | Non-Final OA | Cellix Bio Private Limited |
| 18188716 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | Non-Final OA | Eisai R&D Management Co., Ltd. |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | Non-Final OA | Academisch Ziekenhuis Maastricht |
| 18185935 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN | Non-Final OA | Olatec Therapeutics LLC |
| 17917337 | USE OF BROMODOMAIN INHIBITORS FOR TREATMENT OF HUNTINGTON'S DISEASE | Final Rejection | RUMI SCIENTIFIC HOLDINGS, INC. |
| 17795076 | MASITINIB FOR THE TREATMENT OF A MULTIPLE SCLEROSIS PATIENT SUBPOPULATION | Final Rejection | AB SCIENCE |
| 17806689 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | Final Rejection | IC-MedTech Corp. |
| 17614437 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Final Rejection | Conservatoire National des Arts et Métiers (CNAM) |
| 17517879 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | Non-Final OA | Cassava Sciences, Inc. |
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | Non-Final OA | UNIVERSITE COTE D'AZUR |
| 17378839 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | Final Rejection | BUDDHIST TZU CHI MEDICAL FOUNDATION |
| 17311633 | METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS | Non-Final OA | Aphios Corporation |
| 17288609 | SILDENAFIL FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | Final Rejection | Artroa AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy